Skip to Main Content

Paper Details

Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
AIDS
8
2021
AIDS, DTG, Dolutegravir, E138E, E138T, HIV, HIV-1, HIV-1 integrase, HIV-1 integrase sequences, HIV-1 subtype A1 and D infections, HLA, HXB2 4230-5093, Human, Human leukocyte antigen, L74I, Plasma, cabotegravir, integrase, integrase strand, participants, patients
Author NameAffiliation
Mary CarringtonFrederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute
Mary CarringtonRagon Institute of MGH
Mary CarringtonFrederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute
Mary CarringtonRagon Institute of MGH
Jonathan M Carlson
Peter W HuntUniversity of California san francisco
Jeffrey N MartinUniversity of California san francisco
David R BangsbergOregon Health Sciences University
P Richard HarriganUniversity of British Columbia
  • 1 - 9

Datasets

Release 1.2